Hims & Hers Health Inc began offering a generic version of semaglutide in Canada on Thursday. The telehealth provider is leveraging the patent expiry of Novo Nordisk A/S-B to launch its first international GLP-1 weight-loss offering. This expansion allows the firm to capture market share in a high-demand category with pricing 25% lower than the minimum cost of branded alternatives.

Generic Entry Follows Patent Expiry